Galectin Therapeutics Inc. (GALT)

[BelizeBeachTrader]

I think today's movement up may be result of this


Galectin Therapeutics Coverage Initiated by Analysts at MLV Capital (GALT)
Posted by Alphonse Anthony on Dec 3rd, 2013 // No Comments

Analysts at MLV Capital began coverage on shares of Galectin Therapeutics (NASDAQ:GALT) in a research report issued to clients and investors on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. MLV Capital’s price target points to a potential upside of 151.89% from the stock’s previous close.
Separately, analysts at Ascendiant Capital Markets initiated coverage on shares of Galectin Therapeutics in a research note to investors on Monday, October 7th. They set a “buy” rating and a $13.00 price target on the stock.
Galectin Therapeutics (NASDAQ:GALT) opened at 7.94 on Tuesday. Galectin Therapeutics has a 52-week low of $1.79 and a 52-week high of $13.21. The stock’s 50-day moving average is $9.33 and its 200-day moving average is $7.10. The company’s market cap is $145.4 million.


Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.04. Analysts expect that Galectin Therapeutics will post $-0.69 EPS for the current fiscal year.
Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.



http://zolmax.com/investing/galectin-therapeutics-coverage-initiated-by-analysts-at-mlv-capital-galt/168596/